Puma Biotechnology, Inc. (PBYI)
NASDAQ
Market Cap
$151.47M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
698 of 809
Rank in Industry
379 of 445
Largest Insider Buys in Sector
PBYI Stock Price History Chart
PBYI Stock Performance
About Puma Biotechnology, Inc.
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Insider Activity of Puma Biotechnology, Inc.
Over the last 12 months, insiders at Puma Biotechnology, Inc. have bought $0 and sold $1.12M worth of Puma Biotechnology, Inc. stock.
On average, over the past 5 years, insiders at Puma Biotechnology, Inc. have bought $0 and sold $1.03M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 56 shares for transaction amount of $4,619 was made by BRYCE RICHARD PAUL (SR VP, CLINICAL RESEARCH & DEV) on 2014‑04‑11.
List of Insider Buy and Sell Transactions, Puma Biotechnology, Inc.
| 2024-06-13 | Sale | Stuglik Brian M | director | 9,900 0.02% | $3.39 | $33,528 | -9.94% | |
| 2024-06-13 | Sale | Dorval Allison | director | 11,000 0.0222% | $3.37 | $37,096 | -9.94% | |
| 2024-06-13 | Sale | MOYES JAY M | director | 22,000 0.0439% | $3.34 | $73,467 | -9.94% | |
| 2024-06-13 | Sale | WILSON TROY EDWARD | director | 27,000 0.0537% | $3.33 | $89,902 | -9.94% | |
| 2024-06-13 | Sale | Senderowicz Adrian | director | 27,000 0.0537% | $3.33 | $89,818 | -9.94% | |
| 2024-01-03 | Sale | AUERBACH ALAN H | President and CEO | 41,396 0.0889% | $4.49 | $185,698 | +12.99% | |
| 2024-01-03 | Sale | NOUGUES MAXIMO F | Chief Financial Officer | 15,682 0.0337% | $4.49 | $70,348 | +12.99% | |
| 2024-01-03 | Sale | HUNT DOUGLAS M | See Remarks | 8,358 0.018% | $4.49 | $37,493 | +12.99% | |
| 2024-01-03 | Sale | Ludwig Jeffrey Jerome | Chief Commercial Officer | 12,956 0.0278% | $4.49 | $58,119 | +12.99% | |
| 2024-01-03 | Sale | Wong Alvin F | Chief Scientific Officer | 7,733 0.0166% | $4.49 | $34,689 | +12.99% | |
| 2023-12-04 | Sale | Wong Alvin F | Chief Scientific Officer | 280 0.0006% | $3.76 | $1,053 | +26.42% | |
| 2023-11-07 | Sale | MILLER MICHAEL PATRICK | director | 25,000 0.0516% | $2.83 | $70,803 | +65.34% | |
| 2023-07-03 | Sale | AUERBACH ALAN H | President and CEO | 60,698 0.1318% | $3.31 | $200,983 | +20.18% | |
| 2023-07-03 | Sale | NOUGUES MAXIMO F | Chief Financial Officer | 14,680 0.0319% | $3.31 | $48,608 | +20.18% | |
| 2023-07-03 | Sale | Ludwig Jeffrey Jerome | Chief Commercial Officer | 12,103 0.0263% | $3.31 | $40,075 | +20.18% | |
| 2023-07-03 | Sale | HUNT DOUGLAS M | See Remarks | 7,809 0.017% | $3.31 | $25,857 | +20.18% | |
| 2023-07-03 | Sale | Wong Alvin F | Chief Scientific Officer | 6,938 0.0151% | $3.31 | $22,973 | +20.18% | |
| 2023-06-13 | Sale | MILLER MICHAEL PATRICK | director | 13,500 0.0285% | $3.45 | $46,630 | +10.83% | |
| 2023-06-13 | Sale | Stuglik Brian M | director | 9,900 0.0209% | $3.46 | $34,252 | +10.83% | |
| 2023-06-13 | Sale | Dorval Allison | director | 10,000 0.0211% | $3.45 | $34,500 | +10.83% |
Insider Historical Profitability
122.45%
| AUERBACH ALAN H | President and CEO | 6936947 14.5822% | $3.14 | 0 | 57 | |
| NOUGUES MAXIMO F | Chief Financial Officer | 128666 0.2705% | $3.14 | 0 | 27 | |
| HUNT DOUGLAS M | See Remarks | 103319 0.2172% | $3.14 | 0 | 31 | |
| Ludwig Jeffrey Jerome | Chief Commercial Officer | 99970 0.2101% | $3.14 | 0 | 5 | |
| Wong Alvin F | Chief Scientific Officer | 98214 0.2065% | $3.14 | 0 | 9 | |
| MILLER MICHAEL PATRICK | director | 43358 0.0911% | $3.14 | 0 | 4 | |
| Stuglik Brian M | director | 49058 0.0672% | $3.14 | 0 | 3 | |
| Dorval Allison | director | 33000 0.0357% | $3.14 | 0 | 2 | |
| MOYES JAY M | director | 21322 0.0343% | $3.14 | 0 | 6 | |
| WILSON TROY EDWARD | director | 350 0.0007% | $3.14 | 0 | 5 | |
| Senderowicz Adrian | director | 0 0% | $3.14 | 0 | 5 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 10 percent owner | 3696580 7.7706% | $3.14 | 21 | 9 | +122.06% |
| Malley Thomas | director | 156551 0.3291% | $3.14 | 4 | 0 | +51.73% |
| BRYCE RICHARD PAUL | SEE REMARKS | 121662 0.2557% | $3.14 | 2 | 39 | +159.55% |
| EYLER CHARLES R | SEE REMARKS | 31957 0.0672% | $3.14 | 0 | 10 | |
| CHARNAS ROBERT | 26453 0.0556% | $3.14 | 0 | 2 | ||
| Lo Steven | Chief Commercial Officer | 19557 0.0411% | $3.14 | 0 | 6 | |
| Miller Ann Calby | director | 12874 0.0271% | $3.14 | 0 | 1 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| The Vanguard Group | $18.5M | 7.24 | 3.49M | -8.18% | -$1.65M | <0.0001 | |
| Millennium Management LLC | $16.79M | 6.57 | 3.17M | +0.1% | +$17,034.20 | 0.01 | |
| Frazier Life Sciences Management L P | $14.93M | 5.84 | 2.82M | New | +$14.93M | 0.77 | |
| Acadian Asset Management | $10.37M | 4.06 | 1.96M | +2.05% | +$207,896.13 | 0.04 | |
| Renaissance Technologies | $9.17M | 3.59 | 1.73M | +3.36% | +$297,863.61 | 0.02 | |
| Camber Capital Management Lp | $8.74M | 3.42 | 1.65M | -41.18% | -$6.12M | 0.31 | |
| BlackRock | $8.57M | 3.35 | 1.62M | +4.73% | +$387,037.83 | <0.0001 | |
| Eversept Partners LP | $7.56M | 2.96 | 1.43M | -15.84% | -$1.42M | 0.57 | |
| Great Point Partners | $7.12M | 2.79 | 1.34M | +22.9% | +$1.33M | 1.19 | |
| Athyrium Capital Management LP | $6.66M | 2.61 | 1.26M | -29.89% | -$2.84M | 35.64 | |
| Morgan Stanley | $3.27M | 1.28 | 617,602 | +64.13% | +$1.28M | <0.0001 | |
| Dimensional Fund Advisors | $3.01M | 1.18 | 568,293 | +14.18% | +$374,026.19 | <0.01 | |
| GlobeFlex Capital | $2.61M | 1.02 | 491,751 | -8.69% | -$248,082.37 | 0.26 | |
| Geode Capital Management | $2.4M | 0.94 | 452,971 | +2.01% | +$47,313.33 | <0.0001 | |
| Goldman Sachs | $2.39M | 0.93 | 450,580 | +288.58% | +$1.77M | <0.0001 | |
| Jane Street Capital | $2.28M | 0.89 | 429,251 | +211.95% | +$1.55M | <0.01 | |
| Qube Research & Technologies | $2.05M | 0.8 | 387,178 | +214.37% | +$1.4M | <0.01 | |
| Connor Clark & Lunn Investment Management Ltd | $2.05M | 0.8 | 385,863 | +96.21% | +$1M | 0.01 | |
| Susquehanna International Group | $2.03M | 0.79 | 382,679 | +159.34% | +$1.25M | <0.01 | |
| American Century Investments | $1.97M | 0.77 | 372,249 | +509.72% | +$1.65M | <0.01 | |
| SEI Investments Company | $1.54M | 0.6 | 289,677 | -0.75% | -$11,612.26 | <0.01 | |
| Two Sigma Advisers LP | $1.35M | 0.53 | 255,300 | -10.36% | -$156,350.00 | <0.01 | |
| Marshall Wace | $1.26M | 0.49 | 238,491 | -31.59% | -$583,694.62 | <0.01 | |
| Arrowstreet Capital, Limited Partnership | $1.22M | 0.48 | 230,425 | New | +$1.22M | <0.01 | |
| Man Group Plc | $1.12M | 0.44 | 211,682 | +25.47% | +$227,751.68 | <0.01 | |
| BNY Mellon | $1M | 0.39 | 188,893 | +306.81% | +$755,037.32 | <0.0001 | |
| Winton Capital Management | $997,900.00 | 0.39 | 188,283 | New | +$997,900.00 | 0.06 | |
| Gsa Capital Partners Llp | $994,000.00 | 0.39 | 187,585 | -28.5% | -$396,105.70 | 0.08 | |
| State Street | $914,155.00 | 0.36 | 172,482 | +6.16% | +$53,000.02 | <0.0001 | |
| Wellington Management Company | $905,055.00 | 0.35 | 170,765 | New | +$905,055.00 | <0.0001 | |
| Federated Hermes | $852,897.00 | 0.33 | 160,924 | -0.38% | -$3,264.80 | <0.01 | |
| Rice Hall James & Associates, LLC | $742,562.00 | 0.29 | 140,106 | -57.53% | -$1.01M | 0.05 | |
| Bridgeway Capital Management | $738,820.00 | 0.29 | 139,400 | +12.06% | +$79,500.00 | 0.01 | |
| Laurion Capital Management LP | $695,228.00 | 0.27 | 131,175 | 0% | +$0 | 0.02 | |
| Citigroup | $691,507.00 | 0.27 | 130,473 | -23.72% | -$215,074.03 | <0.01 | |
| Hrt Financial Llc | $674,000.00 | 0.26 | 127,231 | New | +$674,000.00 | <0.01 | |
| Bank of Montreal | $605,319.00 | 0.22 | 107,900 | +32.55% | +$148,665.00 | <0.0001 | |
| Fidelity Investments | $485,957.00 | 0.19 | 91,690 | +63.52% | +$188,764.80 | <0.0001 | |
| Cubist Systematic Strategies | $466,554.00 | 0.18 | 88,029 | +148.75% | +$278,997.48 | <0.01 | |
| Northern Trust | $442,746.00 | 0.17 | 83,537 | -0.27% | -$1,197.80 | <0.0001 | |
| Two Sigma | $432,978.00 | 0.17 | 81,694 | -62.03% | -$707,433.07 | <0.01 | |
| O Shaughnessy Asset Management Llc | $408,529.00 | 0.16 | 77,081 | +127.7% | +$229,113.53 | 0.01 | |
| Marathon Trading Investment Management Llc | $372,590.00 | 0.15 | 70,300 | New | +$372,590.00 | 0.15 | |
| Assenagon Asset Management S.A. | $371,769.00 | 0.15 | 70,145 | -17.51% | -$78,938.31 | <0.01 | |
| Macquarie Group | $325,008.00 | 0.13 | 62,784 | +2.5% | +$7,915.03 | <0.0001 | |
| Squarepoint Ops LLC | $321,360.00 | 0.13 | 60,634 | +113.52% | +$170,850.69 | <0.01 | |
| Xtx Topco Ltd | $287,011.00 | 0.11 | 54,153 | -1.35% | -$3,916.70 | 0.02 | |
| Brevan Howard Capital Management Lp | $264,338.00 | 0.1 | 49,875 | New | +$264,338.00 | 0.02 | |
| LAZARD ASSET MANAGEMENT LLC | $262,000.00 | 0.1 | 49,466 | +5,128.96% | +$256,989.45 | <0.0001 | |
| Schonfeld Group | $247,000.00 | 0.1 | 46,604 | +132.34% | +$140,687.82 | <0.01 |